Biotechnology & Medical Research

Txcell SA receives EU orphan drug designation for Col-Treg in treatment of non-infectious uveitis

Txcell SA:Says that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.

Wednesday, 17 Dec 2014 11:45am EST

Novogen Limited raises A$4.1 mln in private placement to US institutions

Novogen Limited:Entered into definitive agreements to sell to institutional investors in Unites States in private placement for aggregate gross proceeds of about A$4.1 mln.Closing of offering is expected to occur on or about Dec. 22.Under terms of offering, company will sell aggregate of about 32.85...

Wednesday, 17 Dec 2014 10:00am EST

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.